Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04393441 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
A Phase 3 study of Dry Eye Disease (DED), sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT04393441 is a Phase 3 study of Dry Eye Disease (DED) that has completed, run by Allergan. The registered enrollment target is 400 participants, above the 358-participant average among 3 other Dry Eye Disease (DED) trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT04393441, a Phase 3 study of Dry Eye Disease (DED), has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).
Conditions Studied
Interventions
- DRUG 011516X (New Artificial Tear Formulation)
- DRUG Systane Ultra Multidose
- DRUG REFRESH PLUS®
Study Locations (20)
California
- Milton M. Hom, OD, FAAO - Azusa
- Global Research Management - Glendale
- Eye Research Foundation - Newport Beach
- North Bay Eye Associates, Inc. - Petaluma
- Eric M. White OD Inc - San Diego
- Wolstan & Goldberg Eye Associates - Torrance
Florida
- Nature Coast Clinical Research - Crystal River
- Bowden Eye & Associates - Jacksonville
- South Florida Research Center, Inc. - Miami
- Vista Health Research, LLC - Miami
- Clinical Research Center of Florida - Pompano Beach
Georgia
- Georgia Eye Partners - Atlanta
- Clayton Eye Clinical Research, LLC - Morrow
Kansas
- Alliance for Multispecialty Research, LLC - Newton
- Kannarr Eye Care, LLC - Pittsburg
Missouri
- Moyes Eye Center - Kansas City
- Ophthalmology Associates - Saint Charles
Kentucky
- Senior Health Services - Louisville
Nevada
- Eye Care Associates of Nevada - Sparks
New York
- Rochester Ophthalmological Group, PC - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04393441
The ClinicalTrials.gov registry entry for NCT04393441 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 358-participant average among 3 other Dry Eye Disease (DED) trials with a reported enrollment target (12% higher). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease (DED) appearing as the primary indexed condition, and to 3 interventions - of which 011516X (New Artificial Tear Formulation) is the first listed.
NCT04393441 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04393441 about?
NCT04393441 is a clinical study titled "Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease". The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).
What is the current status of trial NCT04393441?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2020-06-29. Estimated completion is 2021-06-15.
What conditions does trial NCT04393441 study?
This clinical trial studies the following conditions: Dry Eye Disease (DED).
What interventions are being tested in trial NCT04393441?
The interventions under investigation include: 011516X (New Artificial Tear Formulation) (DRUG), Systane Ultra Multidose (DRUG), REFRESH PLUS® (DRUG).
Who is sponsoring clinical trial NCT04393441?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04393441 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease (DED)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
COMPLETED · Phase 3
-
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
COMPLETED · Phase 3
-
Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.